The supernatant was used directly after clarification in some exp

The supernatant was used directly after clarification in some experiments, or in some cases, the fusion proteins were purified via the 6 × Histidine tag using Nickel-NTA agarose beads (Qiagen, Valencia, CA) and Poly-Prep® Chromatography

columns (BioRad, Hercules, CA) using the manufacturer’s recommendations. Interleukin-2 or the IL-2Rα chain was detected using either the anti-IL-2 monoclonal antibody (JES6-1A12; BD Pharmingen) or the anti-mouse IL-2Rα monoclonal antibody (PC61; BD Pharmingen), respectively. Wells of a 96-well plate were coated with either antibody (2·5 μg/ml) in PBS. Wells were blocked with 5% non-fat milk in PBS with 0·2% Tween (PBS-M-Tw) and fusion proteins were added for 1–2 hr at 37°. After cAMP inhibitor washing, an anti-mouse IL-2 Kinase Inhibitor Library concentration biotin-labelled antibody (JES5H4; BD Pharmingen) was added and binding was detected using Strepavidin HRP (Southern Biotechnology Associates, Birmingham, AL). The ELISA plate was developed by adding 50 μl o-phenylenediamine (Sigma-Aldrich) in 0·1 m citrate buffer pH

4·5 and 0·04% H2O2, stopped by adding 50 μl/well 2 M H2SO4 and the absorbance was read at 490 nm. Immunoblot analyses were performed as reported previously with minor modifications.27 The following monoclonal antibodies were used: rat anti-mouse IL-2 antibody (JES6-1A12; BD Pharmingen), rat anti-mouse IL-2Rα (PC61; BD Pharmingen), and mouse anti-6 × His monoclonal antibody (MM5-156P; Covance, Princeton, NJ). Detection was performed using a goat anti-rat

HRP-conjugated antibody (Jackson Immuno Research, West Grove, PA) and developed using the Amersham ECL Plus Western blotting detection reagent (GE Healthcare) following the manufacturer’s recommendations. A determination of fusion protein concentration either was established using immunoblot analyses and quantitative densitometry and compared with recombinant IL-2. For MMP immunoblot analyses, extracts or supernatants were probed with goat anti-mouse MMP2 or MMP9 antibodies (R&D Systems, Minneapolis, MN). Fusion proteins were digested with PSA (Cortex Biochem, San Leandro, CA) or prostate extracts in 50 mm Tris–HCl, 100 mm NaCl pH 7·8 at 37°. For digestion of the fusion protein containing the MMP cleavage sequence, MMP9 or MMP2 (R&D Systems) was activated with p-aminophenylmercuric acetate and this activated protease or equivalent amount of activating solution without the protease was used to digest the fusion protein for 1 hr at 37° for MMP9 and 10 min for MMP2. Aliquots of digests were loaded on 15% Laemmli gels for Western blotting.

Related posts:

1. Following perfusion fixation, spinal cords remained in situ for t
2. Clarification of whether there is a hepatoprotective threshold an
3. 4a, lane 4), barely delivered in the supernatant and was in an in
4. Upon sequencing the coding areas in DNA binding domains of p53,no mutations have
5. Total length cDNA encoding human WIPI was amplified by PCR from t